Jason Luke, Chief Medical Officer at Strand Therapeutics, shared on X about his career update by Strand Therapeutics, adding:
“Extremely excited for this new opportunity and career challenge!
Strand Therapeutics is a field-leader in RNA engineering, lipid nanoparticle technology, and now clinical cancer immunotherapy.
Our lead program, STX-001, is rapidly advancing with multiple clinical programs coming.
Time to work!”
Quoting Strand Therapeutics‘s post:
“Proud to share that Jason Luke will be joining Strand as Chief Medical Officer!
Previously a professor at UPMC, he brings decades of expertise in cancer immunotherapies to the team.”
More posts featuring Jason Luke on OncoDaily.